10-K · February 18, 2026
Innospec’s 2025 Form 10-K emphasizes a three-segment specialty chemicals strategy (Performance Chemicals, Fuel Specialties, Oilfield Services) focused on new product development, selective M&A and geographic expansion.…
Earnings analysis · 10-Q
Filed May 8, 2026 · Our reading of the company's report
The latest report
Innospec (IOSP) reported strong Q1 2026 performance, exceeding estimates with revenue of $453.2 million and EPS of $1.05. Both metrics showed year-over-year growth partly driven by strong Fuel Specialties sales despite…
Innospec (IOSP) reported strong Q1 2026 performance, exceeding estimates with revenue of $453.2 million and EPS of $1.05. Both metrics showed year-over-year growth partly driven by strong Fuel Specialties sales despite adverse weather impacts on Performance Chemicals. The company anticipates continued sequential growth in the coming quarter, though it faces some challenges related to operating expenses and foreign exchange rates.
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Q1 2026 revenue reached $453.2 million, a 3% increase from $440.8 million in Q1 2025, surpassing estimates by 4.87%.
Reported EPS for Q1 2026 stood at $1.05, exceeding the estimate of $1.01, reflecting a surprise of 3.96%.
Fuel Specialties revenue increased to $181.6 million in Q1 2026, up from $170.3 million in Q1 2025, representing a 7% growth.
Operating cash flow was $17.6 million for Q1 2026, albeit down from $28.3 million in Q1 2025.
Cash and cash equivalents remained relatively stable at $289.1 million as of March 31, 2026, compared to $292.5 million at year-end 2025.
Adjusted working capital rose by $20.1 million compared to the previous quarter, resulting in a total adjusted working capital of $384.8 million.
Gross profit declined to $123.5 million in Q1 2026 from $125.1 million in Q1 2025, a decrease of 1.3%.
Corporate costs rose by 26% year-over-year to $22.3 million, reflecting higher legacy costs and legal expenses.
Performance Chemicals segment saw net sales of $169.4 million, a marginal increase but significantly impacted by 15% lower volumes due to winter weather disruptions.
Company expressed optimism for sequential growth in Q2 2026, but specific guidance figures were not provided.
Innospec’s 2025 Form 10-K emphasizes a three-segment specialty chemicals strategy (Performance Chemicals, Fuel Specialties, Oilfield Services) focused on new product development, selective M&A and geographic expansion.…
Innospec’s Q3 2025 results showed revenue essentially flat at $441.9 million (Q3 2024: $443.4M) but operating profit and EPS collapsed due to non‑recurring and impairment charges. The company recorded impairments of…
Innospec reported Q1 net sales of $440.8 million (Q1 2024: $500.2M), with gross profit of $125.1 million and net income of $32.8 million. Revenue and margins contracted year-over-year; operating cash flow weakened to…
Innospec continues to position itself as a focused specialty chemicals group operating three reportable segments (Performance Chemicals, Fuel Specialties and Oilfield Services) and is investing in R&D and selective M&A…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.